A Phase II Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma

被引：0
|
作者：
Rosenthal, Allison C. [1 ]
Dueck, Amylou Constance [1 ]
Gano, Katherine [1 ]
Nichols, Craig [2 ]
Johnson, Daniel [1 ]
Toro, Angela [1 ]
Reddy, Sravan Nagi [1 ]
Slack, James L. [1 ]
Leis, Jose F. [1 ]
Northfelt, Donald W. [1 ]
Bergsagel, P. Leif [2 ]
Tiedemann, Rodger [3 ]
Johnston, Patrick B. [2 ]
Habermann, Thomas M. [2 ]
Witzig, Thomas E. [2 ]
Reeder, Craig B. [1 ]
机构：
[1] Mayo Clin Arizona, Scottsdale, AZ USA
[2] Mayo Clin, Rochester, MN USA
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.4748.4748
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma
    Blum, Kristie A.
    Baiocchi, Robert A.
    Alinari, Lapo
    Lin, Thomas S.
    Porcu, Pierluigi
    Jones, Jeffrey
    Flynn, Joseph
    Hicks, William
    Lucas, Margaret S.
    Wei, Lai
    Johnston, Jeffrey S.
    Byrd, John C.
    BLOOD, 2008, 112 (11) : 1049 - 1050
  • [32] Combined therapy with rituximab, fludarabine, cyclophosphamide, and dexamethasone (R-FCD) in patients with low-grade-lymphoma.
    Ebeling, P
    Schuett, P
    Seeber, S
    Nowrousian, MR
    BLOOD, 2002, 100 (11) : 296B - 296B
  • [33] Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)
    Morrison, Vicki A.
    Jung, Sin-Ho
    Johnson, Jeffrey
    LaCasce, Ann
    Blum, Kristie A.
    Bartlett, Nancy L.
    Pitcher, Brandelyn N.
    Cheson, Bruce D.
    LEUKEMIA & LYMPHOMA, 2015, 56 (04) : 958 - 964
  • [34] Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma: A Phase II Trial of the Sarah Cannon Research Institute
    Flinn, Ian W.
    Thompson, Dana S.
    Boccia, Ralph V.
    Miletello, Gerald
    Lipman, Andrew
    Flora, Douglas
    Cuevas, Daniel
    Papish, Steven W.
    Berdeja, Jesus G.
    BLOOD, 2012, 120 (21)
  • [35] Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma
    Craig, Michael
    Hanna, Wahid T.
    Cabanillas, Fernando
    Chen, Chien-Shing
    Esseltine, Dixie-Lee
    Neuwirth, Rachel
    O'Connor, Owen A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (06) : 920 - 928
  • [36] A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
    Holkova, Beata
    Perkins, Edward B.
    Sokol, Lubomir
    Richards, Kristy L.
    Parekh, Samir
    Elstrom, Rebecca
    Badros, Ashraf Z.
    Espinoza-Delgado, Igor
    Schell, Michael J.
    Kimball, Amy
    Tombes, Mary Beth
    Shrader, Ellen
    Sankala, Heidi
    Coppola, Domenico
    Kmieciak, Maciej
    Sullivan, Daniel
    Roberts, John D.
    Grant, Steven
    BLOOD, 2011, 118 (21) : 353 - 354
  • [37] A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma
    Yazbeck, Victor
    Shafer, Danielle
    Perkins, Edward B.
    Coppola, Domenico
    Sokol, Lubomir
    Richards, Kristy L.
    Shea, Thomas
    Ruan, Jia
    Parekh, Samir
    Strair, Roger
    Flowers, Christopher
    Morgan, David
    Kmieciak, Maciej
    Bose, Prithviraj
    Kimball, Amy
    Badros, Ashraf Z.
    Baz, Rachid
    Lin, Hui-Yi
    Zhao, Xiuhua
    Reich, Richard R.
    Tombes, Mary Beth
    Shrader, Ellen
    Sankala, Heidi
    Roberts, John D.
    Sullivan, Daniel
    Grant, Steven
    Holkova, Beata
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (09): : 569 - +
  • [38] Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on An Ongoing Phase I/II Trial
    Hess, Georg
    Keller, Ulrich
    Atta, Johannes
    Buske, Christian
    Borchmann, Peter
    Medler, Christoph
    Witzens-Harig, Mathias
    Dreyling, Martin H.
    BLOOD, 2011, 118 (21) : 1159 - 1159
  • [39] Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on an Ongoing Phase I/II Trial
    Hess, Georg
    Keller, Ulrich
    Atta, Johannes
    Bitz, Ulrich
    Lerchenmueller, Christian
    Karola, Wagner
    Medler, Christoph
    Ruckes, Christian
    Witzens-Harig, Mathias
    Huebel, Kai
    LaRosee, Paul
    Dreyling, Martin H.
    BLOOD, 2015, 126 (23)
  • [40] Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group
    Scheubeck, Gabriel
    Hoffmann, Martin
    Jurinovic, Vindi
    Fischer, Luca
    Unterhalt, Michael
    Schmidt, Christian
    Boeck, Hans-Peter
    Duehrsen, Ulrich
    Kaesberger, Joachim
    Kremers, Stephan
    Lindemann, Hans-Walter
    Mantovani, Luisa
    Hiddemann, Wolfgang
    Hoster, Eva
    Dreyling, Martin
    ANNALS OF HEMATOLOGY, 2024, 103 (07) : 2373 - 2380
12345